US 11,701,424 B2
Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
Mark White, Antioch, CA (US); Sandeep Kumar, San Bruno, CA (US); Christopher Chan, South San Francisco, CA (US); Spencer Liang, San Mateo, CA (US); Lance Stapleton, Oakland, CA (US); Andrew W. Drake, Mountain View, CA (US); Yosi Gozlan, Tel Aviv (IL); Ilan Vaknin, Tel Aviv (IL); Shirley Sameah-Greenwald, Kfar Saba (IL); Liat Dassa, Tel Aviv (IL); Zohar Tiran, Oranit (IL); Gad S. Cojocaru, Tel Aviv (IL); Maya Kotturi, Belmont, CA (US); Hsin-Yuan Cheng, San Mateo, CA (US); Kyle Hansen, San Francisco, CA (US); David Nisim Giladi, Netaniya (IL); Einav Safyon, Raanana (IL); Eran Ophir, Even Yehuda (IL); Leonard Presta, San Francisco, CA (US); Richard Theolis, Santa Cruz, CA (US); Radhika Desai, Brisbane, CA (US); and Patrick Wall, Mill Valley, CA (US)
Assigned to COMPUGEN LTD., Holon (IL)
Filed by Compugen Ltd., Holon (IL)
Filed on Jun. 17, 2020, as Appl. No. 16/904,511.
Application 16/904,511 is a division of application No. 15/680,187, filed on Aug. 17, 2017, granted, now 10,751,415.
Claims priority of provisional application 62/538,561, filed on Jul. 28, 2017.
Claims priority of provisional application 62/513,771, filed on Jun. 1, 2017.
Claims priority of provisional application 62/513,916, filed on Jun. 1, 2017.
Claims priority of provisional application 62/513,775, filed on Jun. 1, 2017.
Claims priority of provisional application 62/477,974, filed on Mar. 28, 2017.
Claims priority of provisional application 62/417,217, filed on Nov. 3, 2016.
Claims priority of provisional application 62/376,334, filed on Aug. 17, 2016.
Claims priority of provisional application 62/376,335, filed on Aug. 17, 2016.
Prior Publication US 2021/0000952 A1, Jan. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39558 (2013.01) [A61K 39/39541 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/572 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/035 (2013.01); C07K 2319/33 (2013.01); Y02A 50/30 (2018.01)] 30 Claims
 
1. A method of activating T-cells of a patient with cancer comprising administering an anti-PD-L1 antibody and an anti-PVRIG antibody to said patient, wherein said anti-PVRIG antibody comprises:
i) a heavy chain comprising SEQ ID NO: 9, and
ii) a light chain comprising SEQ ID NO: 14.